178 related articles for article (PubMed ID: 15516959)
1. Antitumour effects of antiretroviral therapy.
Monini P; Sgadari C; Toschi E; Barillari G; Ensoli B
Nat Rev Cancer; 2004 Nov; 4(11):861-75. PubMed ID: 15516959
[TBL] [Abstract][Full Text] [Related]
2. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
3. HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
Barbaro G; Barbarini G
Oncol Rep; 2007 May; 17(5):1121-6. PubMed ID: 17390054
[TBL] [Abstract][Full Text] [Related]
4. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
Kong HH; Myers SA
Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
[TBL] [Abstract][Full Text] [Related]
7. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
Cheung MC; Pantanowitz L; Dezube BJ
Oncologist; 2005; 10(6):412-26. PubMed ID: 15967835
[TBL] [Abstract][Full Text] [Related]
8. [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
Tserenpuntsag B; Kołacińska A; Jabłonowska E
Przegl Epidemiol; 2007; 61(3):529-34. PubMed ID: 18069390
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy in HIV.
Yu A; Berbari E; Temesgen Z
J Med Liban; 2006; 54(2):74-9. PubMed ID: 17086997
[TBL] [Abstract][Full Text] [Related]
11. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice.
Mounier N; Katlama C; Costagliola D; Chichmanian RM; Spano JP
Crit Rev Oncol Hematol; 2009 Oct; 72(1):10-20. PubMed ID: 19070506
[TBL] [Abstract][Full Text] [Related]
12. [HIV protease inhibitors for the treatment of Kaposi's sarcoma].
Grosso G; Sgadari C; Barillari G; Toschi E; Bacigalupo I; Carlei D; Palladino C; Baccarini S; Malavasi L; Moracci G; Leone P; Chiozzini C; Monini P; Ensoli B
Recenti Prog Med; 2003 Feb; 94(2):69-74. PubMed ID: 12908373
[TBL] [Abstract][Full Text] [Related]
13. Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy.
Klibanov OM; Clark-Vetri R
Pharmacotherapy; 2007 Jan; 27(1):122-36. PubMed ID: 17192166
[TBL] [Abstract][Full Text] [Related]
14. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
[TBL] [Abstract][Full Text] [Related]
15. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
Loke WC; Spittle MF; Mitchell S; Kulasegaram R
Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
[TBL] [Abstract][Full Text] [Related]
16. The oncology impact of highly active antiretroviral therapy.
Schlichemeyer R; Chambers C; Gill MJ
J Oncol Pharm Pract; 2007 Mar; 13(1):17-25. PubMed ID: 17621563
[TBL] [Abstract][Full Text] [Related]
17. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
18. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
[TBL] [Abstract][Full Text] [Related]
19. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.
Kotb R; Vincent I; Dulioust A; Peretti D; Taburet AM; Delfraissy JF; Goujard C
Eur J Haematol; 2006 Mar; 76(3):269-71. PubMed ID: 16451402
[TBL] [Abstract][Full Text] [Related]
20. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]